R3 Vascular Inc.

R3 Vascular Inc. is a medical device company based in Mountain View, California. The company specializes in developing advanced bioresorbable vascular scaffold (BVS) technology aimed at treating peripheral arterial disease (PAD). Their core product, the MAGNITUDE® drug-eluting bioresorbable scaffold, is designed to compete with traditional metal drug-eluting stents, particularly for below-the-knee arterial blockages. The MAGNITUDE scaffold features a unique polymer and manufacturing process that ensures a balance of strength and flexibility, with an ultra-thin strut thickness of 98 microns. R3 Vascular is currently conducting pivotal clinical trials, including the ELITE-BTK trial, which focuses on patients with severe below-the-knee vessel blockages. This trial aims to demonstrate the safety and efficacy of the MAGNITUDE scaffold, particularly for patients at risk of limb amputation. The company is led by President and CEO Christopher Owens, who has extensive experience in medical device innovation, and its founder, Kamal Ramzipoor, serves as Chief Technology Officer. R3 Vascular's technology aims to enhance clinical outcomes for patients suffering from chronic limb-threatening ischemia and other forms of PAD.

• Employees 25
• Founded 2019
• Annual Revenue $4500000
• Total Funding $179967698